<DOC>
	<DOCNO>NCT01154985</DOCNO>
	<brief_summary>This control study determine effectiveness safety ethyl icosapentate ( EPA-E ) treatment adult patient non-alcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Double-Blind , Placebo-Controlled Study Two Doses EPA-E Patients With Non Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description>This phase II , double-blinded , placebo-controlled study investigate safety , efficacy , pharmacokinetic profile two dose EPA-E adult subject NASH . Subjects require liver biopsy proven NASH 6 month period prior screen . Up 70 subject enrol treatment arm 1:1:1 ratio , total 210 subject . Subjects stratify randomization presence absence diabetes . Duration treatment 12 month .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Diagnosis definite NASH Patients diabetes take stable dos antidiabetic agent eligible No significant concomitant medical illness Diagnosis cirrhosis . Serum ALT &gt; 300 U/L Use drug associate steatohepatitis Use follow anitNASH agent : 1 . Vitamin E &gt; 60 IU per day 2 . Omega3acid ethyl ester omega3polyunsaturated fatty acid ( PUFA ) contain supplement &gt; 200 mg per day 3 . Thiazolidinediones ( e.g . pioglitazone ) Use nonstable dos follow antiNASH agent : HMGCoA reductase inhibitor ( statin ) , fibrates , probucol , ezetimibe , ursodiol ( UDCA ) , taurine , betaine , Nacetylcysteine , sadenosylmethionine ( SAME ) , milk thistle , antiTNF therapy , probiotic . Other liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>alanine transaminase</keyword>
	<keyword>triglyceride</keyword>
	<keyword>lipid</keyword>
	<keyword>EPA</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>ethyl icosapentate</keyword>
	<keyword>Non Alcoholic steatohepatitis</keyword>
	<keyword>Non Alcoholic fatty liver disease</keyword>
	<keyword>fatty acid</keyword>
</DOC>